BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
- Update frequency
- every 4 days
- Average duration
- 18 minutes
- Episodes
- 165
- Years Active
- 2023 - 2025
Eyes on the prize: Novo buys Catalent
This week, Greg, Heather and Tyler discuss reaction to Novo Nordisk's purchase of Catalent and speculate on what that means for existing manufacturing contracts, customers and consequences with regul…
Balancing act: Patient access and innovation
This week Lori, Greg and Tyler discuss drug pricing reforms. CMS sent offers to manufacturers of the 10 drugs that have been selected for Medicare price negotiations. What's the best way forward that…
Keep calm and CAR-T on?
Almost 30,000 patients have now been treated with CAR-T cell therapies since it was the first approval in 2017. In November 2023, the FDA launched a probe into malignancies caused by CAR T therapies,…
What can biopharma expect from the job market?
Following a challenging year of layoffs and limited funding, Chantal Dresner, VP of Marketing at BioSpace, discusses the findings of our most recent Employment Outlook Report including unemployment, …
Grab an umbrella, it's raining IPOs!
The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announcements.
Lori, Greg and Tyler also discuss gene th…
Optimistic, but for how long? Our big takeaways from #JPM2024
The team comes together to discuss the dominant themes of what was an incredibly busy week of events in San Francisco.
There was an air of hope and optimism concerning biopharma funding - but will i…
On the ground at #JPM2024 - Day 3 highlights
We're still in San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day three: disruptive AI is still a hot topic including generative AI; M&…
On the ground at #JPM2024 - Day 2 highlights
Once again we're recording from San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day two: AI, cell and gene therapy innovation and pricing…
On the ground at #JPM2024 - Day 1 highlights
Hello from San Francisco! BioSpace is reporting from #JPM2024 bringing you key takeaways and highlights from day one.
Join Lori, Greg and Tyler as they discuss what's moving and shaking.
You can fo…
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics
The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that investors are excited bef…
The top life sciences startups to watch this year
Welcome to 2024! This week we're discussing BioSpace's tenth annual list of the hottest new life sciences companies in the U.S. NextGen Class of 2024 includes organizations that launched between Sep…
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital
How can startup leaders support long-term sustainable growth and investment?
BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen for their advice …
Every move you make: Biopharma industry under heavy scrutiny
Biden administration flexes regulatory muscles, putting pressure on the biopharma industry over ‘price gouging’ and invoking march-in rights; meanwhile Sanofi throws in towel over threat of injunctio…
What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital
What needs to happen for funding in biopharma to bounce back? BioSpace’s Lori Ellis discusses the macroeconomic environment and biopharma funding outlook with venture capital guests Ansbert Gadicke, …
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
That was Week with a capital W. Two major FDA approvals for sickle cell came through on Friday - Casgevy, the first-ever CRISPR-based gene editing therapy from Vertex and CRISPR Therapeutics, and blu…
Fast and furious evolution: How to ensure AI is catalyst for positive societal change with Microsoft and IQVIA
This is the second part of our discussion on the evolution of artificial intelligence and its impact on life sciences with guests from Microsoft and IQVIA.
We dive into regulation, real-time managem…
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA
Over the last year, the reaction to generative AI has changed - and so have behaviors. People are integrating AI to become more productive and it is happening now in healthcare and life sciences. Hea…
GLP-1 and ADC rollercoasters pick up speed
The weight loss market sees more ups and downs - Altimmune joins the fray and sees a stock jump while Pfizer experiences setbacks; and European Medicines Agency seeks additional information as part o…
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior
Patient behavior has always had an influence on clinical trials - so how do we contend with missing and/or irregular data now that it is feeding AI models? And how do providers continue to work with …
Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety
The breadth of AI in healthcare applications is broad. How much human oversight is necessary or preferred when leveraging AI in the interest of patient safety?
Listen to this in-depth discussion on …